Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518353

— · F

2c69c2c5-5d07-5d24-83e9-2441cc83db28

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
F
subtype
F

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.680
  • COAGULATION+0.510
  • ANGIOGENESIS+0.470
  • HYPOXIA+0.460
  • CHOLESTEROL_HOMEOSTASIS+0.430
  • ANDROGEN_RESPONSE+0.380
  • APOPTOSIS+0.380
  • TNFA_SIGNALING_VIA_NFKB+0.380
  • XENOBIOTIC_METABOLISM+0.380
  • APICAL_JUNCTION+0.350

Top 10 suppressed

  • MYC_TARGETS_V2-0.580
  • E2F_TARGETS-0.430
  • G2M_CHECKPOINT-0.390
  • MYC_TARGETS_V1-0.390
  • MITOTIC_SPINDLE-0.260
  • WNT_BETA_CATENIN_SIGNALING-0.260
  • INTERFERON_ALPHA_RESPONSE-0.200
  • DNA_REPAIR-0.170
  • OXIDATIVE_PHOSPHORYLATION-0.100
  • SPERMATOGENESIS-0.070

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-AN-A03X-01A-21R-A00Z-07
breast-umap@18
—A0.910
220060059.TNBC
breast-umap@18
—F0.890
3MNG349
mng-umap@100
——0.890
4SRR8613755
breast-umap@18
—F0.888
520040045.TNBC
breast-umap@18
—F0.888
6SRR8613813
breast-umap@18
—D0.884
7s0099997
melanoma-umap@29
——0.883
8TCGA-BA-5557-01A-01R-1514-07
head-neck@1
——0.881
9TCGA-BH-A0DX-01A-11R-A115-07
breast-umap@18
—A0.880
10SRR2932845
head-neck@1
——0.880

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.680Inavolisib— uncovered
COAGULATION0.510Binimetinib— uncovered
ANGIOGENESIS0.470Remibrutinib— uncovered
HYPOXIA0.460Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.430Remibrutinib— uncovered
ANDROGEN_RESPONSE0.380Inavolisib— uncovered
APOPTOSIS0.380Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.380Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.380Inavolisib— uncovered
APICAL_JUNCTION0.350Inavolisib— uncovered
MYOGENESIS0.340Inavolisib— uncovered
COMPLEMENT0.320Inavolisib— uncovered
GLYCOLYSIS0.320Inavolisib— uncovered
TGF_BETA_SIGNALING0.320Inavolisib— uncovered
UV_RESPONSE_DN0.310Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.300Idelalisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.270Idelalisib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
MTORC1_SIGNALING0.240Inavolisib— uncovered